Display options
Cite
Pan X, Ren D, Li Y, et al. The effect of surgery on primary splenic lymphoma: A study based on SEER database. Cancer Med. 2021;10(20):7060-7070doi: 10.1002/cam4.4238.
Pan, X., Ren, D., Li, Y., & Zhao, J. (2021). The effect of surgery on primary splenic lymphoma: A study based on SEER database. Cancer medicine, 10(20), 7060-7070. https://doi.org/10.1002/cam4.4238
Pan, Xiaotao, et al. "The effect of surgery on primary splenic lymphoma: A study based on SEER database." Cancer medicine vol. 10,20 (2021): 7060-7070. doi: https://doi.org/10.1002/cam4.4238
Pan X, Ren D, Li Y, Zhao J. The effect of surgery on primary splenic lymphoma: A study based on SEER database. Cancer Med. 2021 Oct;10(20):7060-7070. doi: 10.1002/cam4.4238. Epub 2021 Sep 21. PMID: 34547191; PMCID: PMC8525177.
Copy Download .nbib Format: NLM
Share it on

Cancer Med. 2021 Oct;10(20):7060-7070. doi: 10.1002/cam4.4238. Epub 2021 Sep 21.

The effect of surgery on primary splenic lymphoma: A study based on SEER database.

Cancer medicine

Xiaotao Pan, Dongfeng Ren, Ya Li, Jin Zhao

Affiliations

  1. Department of General Surgery, Shaanxi Provincial Cancer Hospital, Xi'an, China.
  2. Department of Oncology, The First Hospital of Yulin, Yulin, China.
  3. Department of Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, China.
  4. Department of Radiotherapy, Shaanxi Provincial Cancer Hospital, Xi'an, China.

PMID: 34547191 PMCID: PMC8525177 DOI: 10.1002/cam4.4238

Abstract

BACKGROUND: Although primary splenic lymphoma (PSL) is rare, it ranks first among splenic primary malignant cancers, and the incidence of lymphoma of spleen has gradually increased in recent years. However, the efficacy of surgery for PSL has not been clinically verified by large sample data, which has affected the formulation of relevant guidelines.

AIM: To assess whether surgery can enhance the prognosis PSL patients.

METHODS: Extracted the data of patients with PSL from The Surveillance, Epidemiology, and End Results (SEER) database, and divided the patients into surgery and non-surgery group. Kaplan-Meier curves and log-rank tests were used to compare the overall survival (OS) and cancer-specific survival (CSS). The propensity score matching (PSM) was used to match the data, then compared the OS and CSS again. The COX proportional hazard regression model was used for univariate and multivariate analysis. Finally, we performed subgroup analysis in different Ahmann stages.

RESULTS: A sum of 2207 patients with PSL were enrolled, of which 1062 (48.1%) patients received surgery, and 1145 (51.9%) patients did not undergo surgery. Overall, patients in the surgery group had better OS and CSS. After the propensity scores matching, surgery was not statistically significant in OS and CSS. In the subgroup analysis, surgery was a protective factor for the OS and CSS in Ahmann I/II. However, surgery was no statistical significance in OS and CSS in Ahmann III. In patients with Ahmann Ⅰ/Ⅱ SMZL, surgery was a protective factor for OS and CSS. In patients with Ahmann Ⅲ SMZL, surgery was also statistically significant of OS and CSS.

CONCLUSIONS: Surgery can significantly improve the prognosis of patients with Ahmann Ⅰ/Ⅱ primary splenic lymphoma, but there was no survival difference in the Ahmann Ⅲ patients with or without surgery. For patients with SMZL, surgery was effective for improving OS and CSS.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Keywords: SEER; primary splenic lymphoma; propensity score matching; surgery

References

  1. Arch Intern Med. 1971 Feb;127(2):259-65 - PubMed
  2. Arch Pathol Lab Med. 1985 Dec;109(12):1076-80 - PubMed
  3. Cancer Invest. 2002;20(5-6):749-53 - PubMed
  4. An Med Interna. 2007 Aug;24(8):405-6 - PubMed
  5. World J Gastroenterol. 2016 Jul 21;22(27):6214-23 - PubMed
  6. Int Surg. 2000 Jul-Sep;85(3):248-51 - PubMed
  7. ANZ J Surg. 2006 Aug;76(8):679-82 - PubMed
  8. Leuk Lymphoma. 2014 Aug;55(8):1854-60 - PubMed
  9. Kaohsiung J Med Sci. 2013 Mar;29(3):150-6 - PubMed
  10. Cancer Med. 2021 Oct;10(20):7060-7070 - PubMed
  11. Cancer. 1969 Oct;24(4):709-18 - PubMed
  12. Yonsei Med J. 2005 Oct 31;46(5):703-9 - PubMed
  13. Cancer. 1988 Oct 1;62(7):1433-8 - PubMed
  14. Blood. 2002 Sep 1;100(5):1648-54 - PubMed
  15. Haematologica. 1994 May-Jun;79(3):286-93 - PubMed
  16. World J Gastroenterol. 2009 Aug 28;15(32):4009-15 - PubMed
  17. Cancer. 1994 Aug 1;74(3):933-9 - PubMed
  18. Vet Surg. 2015 Nov;44(8):976-82 - PubMed
  19. Wiad Lek. 1973 Mar 15;26(6):485-9 - PubMed
  20. Cancer. 1966 Apr;19(4):461-9 - PubMed
  21. Clin Radiol. 1998 Aug;53(8):623-4 - PubMed
  22. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4484-8 - PubMed
  23. Expert Rev Hematol. 2019 Dec;12(12):1011-1022 - PubMed
  24. Am J Hematol. 1991 Oct;38(2):95-100 - PubMed
  25. Cancer. 2001 Jun 1;91(11):2001-9 - PubMed
  26. Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):56-64 - PubMed
  27. Surgery. 1992 Feb;111(2):224-7 - PubMed
  28. World J Clin Cases. 2014 Sep 16;2(9):478-81 - PubMed
  29. Leuk Lymphoma. 2001 May;41(5-6):593-605 - PubMed
  30. J Gastroenterol Hepatol. 1996 Aug;11(8):724-7 - PubMed
  31. Leuk Lymphoma. 1993 Oct;11(3-4):165-71 - PubMed
  32. Rare Tumors. 2011 Apr 4;3(2):e25 - PubMed

Publication Types